Lineage Cell Therapeutics, Inc.
- Last sale
- Nov 12, 2026 · -11.97%
- Market cap
- $250.50M
- 252.95M shares
- Filings
- 1,018
Q3 2026+53.2% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−10.9% FY25 yoy
- $250.50M
- 142.9×
- 23.1×
- 3.7×
- -10.56%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $14,556,000 | reported | |
| FY 2024 | 2024-12-31 | $9,499,000 | reported | |
| FY 2023 | 2023-12-31 | $8,945,000 | reported | |
| FY 2022 | 2022-12-31 | $14,703,000 | reported | |
| FY 2021 | 2021-12-31 | $4,341,000 | reported | |
| FY 2020 | 2020-12-31 | $1,826,000 | reported | |
| FY 2019 | 2019-12-31 | $3,515,000 | reported | |
| FY 2018 | 2018-12-31 | $4,988,000 | reported | |
| FY 2017 | 2017-12-31 | $3,458,000 | reported | |
| FY 2016 | 2016-12-31 | $5,923,000 | reported | |
| FY 2015 | 2015-12-31 | $7,036,000 | reported | |
| FY 2014 | 2014-12-31 | $5,244,000 revised | reported |
Segments
LineFY2025ShareChange
Non-US$2.50M17%—
Foreign———
UNITED STATES———
Total$14.56M
Biological products, except diagnostic substances
Lineage Cell Therapeutics, Inc. is the 58th largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836
CompanyRevenueGrowthNet marginMarket cap
ALECAlector, Inc.$21.0M79.1%679.2%$363.3MLENZLENZ Therapeutics, Inc.$19.1M—430.3%$127.9MPTHSPelthos Therapeutics Inc.$16.8M—257.9%$31.5MRLAYRelay Therapeutics, Inc.$15.4M53.4%1,800.6%$4.0B
LCTXLineage Cell Therapeutics, Inc. (this company)$14.6M53.2%436.5%$250.5M
ELUTElutia Inc.$12.3M15.0%434.2%$39.8MCRBUCaribou Biosciences, Inc.$11.2M11.7%1,327.4%$40.8MTCRXTScan Therapeutics, Inc.$10.3M266.7%1,256.8%$11.1MACOGAlpha Cognition Inc.$10.2M—202.2%$188.3MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR